Innoviva, Inc. stock performance trend indicates that the stock price has rallied 21.83% in the past 12 Weeks , but analyzing the 6 month charts for the stock , the price continues to stay positive and keep the rally at 17.83% . Looking at the past 52 week period, the stock price is up at 5.89% . Relative price strength is a important factor used by wealth management firms while investing in stocks since the indicator compares the stock performance with the overall market. The relative price strength of Innoviva, Inc. has a negative value of -14.1 compared to overall market performance.Innoviva, Inc. is having a Relative Strength Index of 65.59 which indicates the stock is not yet over sold or over bought based on the technical indicators.
Innoviva, Inc. (NASDAQ:INVA) has climbed 2.21% in the past week and advanced 7.56% in the last 4 weeks. In the past week, the company has outperformed the S&P 500 by 1.97% and the outperformance has advanced to 6.33% for the last 4 weeks period.
Company shares have received an average consensus rating of Hold for the current week Innoviva, Inc. (NASDAQ:INVA) : On Friday heightened volatility was witnessed in Innoviva, Inc. (NASDAQ:INVA) which led to swings in the share price. The stock opened for trading at $12.49 and hit $12.95 on the upside , eventually ending the session at $12.95, with a gain of 2.45% or 0.31 points. The heightened volatility saw the trading volume jump to 1,611,486 shares. The 52-week high of the share price is $14.15 and the company has a market cap of $1,414 million. The 52-week low of the share price is at $8.67 .
Company has reported several Insider transactions to the SEC, on Feb 22, 2017, Eric Desparbes (SVP and CFO) sold 1,825 shares at 12.07 per share price.On Nov 22, 2016, Theodore L Jr Witek (Sr. VP & Chief Scientific Off.) sold 3,700 shares at 10.84 per share price.On May 20, 2016, James L Tyree (director) sold 813 shares at 10.47 per share price.
Innoviva Inc Last issued its quarterly earnings results on Feb 9, 2017. The company reported $0.22 EPS for the quarter. Analyst had a consensus estimate of $0.22. The company had revenue of $43.61 million for the quarter, compared to analysts expectations of $41.79 million. The companys revenue was up 90.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.04 EPS.
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The companys portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.